Real-life treatment practice for malignant pleural mesothelioma in Belgium

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3K citations

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gérard Zalcman, Julien Mazières, J. Margery et al. · The Lancet · 2015 · 965 citations

Medicine, Pathology, Pleural Disease +5

A Confidence Interval for the Median Survival Time

Ron Brookmeyer, John Crowley · Biometrics · 1982 · 892 citations

Median Survival Time, Survival Functions, Patient Safety +7

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

Tom Treasure, Loı̈c Lang-Lazdunski, David Waller et al. · The Lancet Oncology · 2011 · 706 citations · Full text

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

Arnaud Scherpereel, Philippe Astoul, Paul Baas et al. · European Respiratory Journal · 2009 · 631 citations · Full text